Viewing Study NCT00004986



Ignite Creation Date: 2024-05-05 @ 11:19 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004986
Status: TERMINATED
Last Update Posted: 2005-06-24
First Post: 2000-03-16

Brief Title: Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients
Sponsor: Romark Laboratories LC
Organization: NIH AIDS Clinical Trials Information Service

Study Overview

Official Title: Open Label Multi-Center Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in Subjects With AIDS in the United States
Status: TERMINATED
Status Verified Date: 2000-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to see if it is safe and effective to treat cryptosporidiosis in AIDS patients with nitazoxanide
Detailed Description: Patients take nitazoxanide daily for 8 weeks with a dose escalation after the first 4 weeks Patients return to the hospital for examinations every 2 weeks during the 8-week treatment period and 6-week follow-up Nitazoxanide therapy is discontinued in patients showing a complete clinical and parasitologic response therapeutic cure after 8 weeks of treatment and in patients showing a therapeutic cure at two consecutive visits Weeks 2 and 4 or Weeks 4 and 6 These patients undergo a physical examination including stool analysis for Cryptosporidium parvum oocysts and routine laboratory tests at Weeks 2 4 and 6 after completion of nitazoxanide therapy Patients who do not show a complete clinical and parasitologic response therapeutic failure after 8 weeks of treatment are allowed to remain on nitazoxanide therapy through the Open Label Compassionate Use of Nitazoxanide in Treatment of Cryptosporidiosis in AIDS Patients UMD-95-009 protocol

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
RM-NTZ-99-003 None None None